OCMS technology screens millions of recombinant antibodies in mammalian cells for expression and antigen binding. OCMS can screen any antibody format (IgG, scFv, VHH), completing the full library analysis in just 4 weeks. Since the beginning of 2024, OCMS has focused on discovering next generation antibody therapeutics targeting proven therapeutic pathways. Recently, OB2401 demonstrated over 5x improvement in performance on the key functional assay relative to the market leader. OCMS Bio, LLC is seeking investment for our program of rapid development of validated leads for antibody therapeutics of proven efficacy and demonstrated high economic value and to commence partnering and development conversations around the first three of those molecules in infectious disease, human metabolism and oncology.